Advisory Research’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15.9M | Buy |
73,072
+2,379
| +3% | +$528K | 1.95% | 19 |
|
|
2025
Q4 | $16.2M | Buy |
70,693
+692
| +1% | +$158K | 2.03% | 18 |
|
|
2025
Q3 | $16.2M | Buy |
70,001
+9,880
| +16% | +$2.01M | 2.13% | 16 |
|
|
2025
Q2 | $11.2M | Buy |
60,121
+8,656
| +17% | +$1.61M | 1.71% | 19 |
|
|
2025
Q1 | $10.8M | Sell |
51,465
-3,465
| -6% | -$674K | 1.9% | 16 |
|
|
2024
Q4 | $9.76M | Sell |
54,930
-489
| -0.9% | -$89.9K | 1.62% | 22 |
|
|
2024
Q3 | $10.9M | Sell |
55,419
-1,226
| -2% | -$229K | 1.94% | 18 |
|
|
2024
Q2 | $9.72M | Buy |
56,645
+3,245
| +6% | +$538K | 1.83% | 18 |
|
|
2024
Q1 | $9.72M | Buy |
53,400
+1,252
| +2% | +$216K | 1.93% | 19 |
|
|
2023
Q4 | $8.08M | Buy |
52,148
+4,775
| +10% | +$696K | 1.25% | 18 |
|
|
2023
Q3 | $7.06M | Sell |
47,373
-7,522
| -14% | -$1.1M | 0.98% | 21 |
|
|
2023
Q2 | $7.4M | Sell |
54,895
-2,402
| -4% | -$352K | 0.95% | 20 |
|
|
2023
Q1 | $9.13M | Sell |
57,297
-55,344
| -49% | -$8.46M | 1.5% | 15 |
|
|
2022
Q4 | $18.2M | Sell |
112,641
-833
| -0.7% | -$128K | 1.71% | 11 |
|
|
2022
Q3 | $15.2M | Sell |
113,474
-64,236
| -36% | -$9.22M | 1.49% | 16 |
|
|
2022
Q2 | $27.2M | Buy |
177,710
+2,021
| +1% | +$309K | 2.66% | 7 |
|
|
2022
Q1 | $28.5M | Sell |
175,689
-8,839
| -5% | -$1.28M | 2.28% | 6 |
|
|
2021
Q4 | $25M | Sell |
184,528
-18,226
| -9% | -$2.15M | 1.97% | 9 |
|
|
2021
Q3 | $21.9M | Sell |
202,754
-1,467
| -0.7% | -$168K | 1.4% | 8 |
|
|
2021
Q2 | $23M | Buy |
204,221
+2,325
| +1% | +$262K | 1.51% | 6 |
|
|
2021
Q1 | $21.8M | Buy |
201,896
+46,298
| +30% | +$4.95M | 1.54% | 9 |
|
|
2020
Q4 | $16.7M | Sell |
155,598
-6,078
| -4% | -$584K | 1.22% | 20 |
|
|
2020
Q3 | $14.2M | Sell |
161,676
-11,694
| -7% | -$1.1M | 1.38% | 18 |
|
|
2020
Q2 | $17M | Buy |
+173,370
| New | +$15.3M | 1.51% | 14 |
|
|
2019
Q1 | – | Sell |
-7,728
| Closed | -$712K | – | 342 |
|
|
2018
Q4 | $712K | Sell |
7,728
-127,618
| -94% | -$11.2M | 0.02% | 270 |
|
|
2018
Q3 | $12.8M | Sell |
135,346
-6,618
| -5% | -$628K | 0.21% | 114 |
|
|
2018
Q2 | $13.2M | Buy |
141,964
+1,274
| +0.9% | +$124K | 0.21% | 115 |
|
|
2018
Q1 | $13.3M | Buy |
140,690
+4,055
| +3% | +$445K | 0.24% | 107 |
|
|
2017
Q4 | $13.2M | Buy |
136,635
+3,010
| +2% | +$284K | 0.22% | 106 |
|
|
2017
Q3 | $11.9M | Buy |
133,625
+37,776
| +39% | +$2.88M | 0.19% | 112 |
|
|
2017
Q2 | $6.95M | Buy |
95,849
+58,014
| +153% | +$3.9M | 0.11% | 136 |
|
|
2017
Q1 | $2.46M | Buy |
+37,835
| New | +$2.38M | 0.04% | 222 |
|
|
2014
Q2 | – | Sell |
-1,355
| Closed | -$70K | – | 323 |
|
|
2014
Q1 | $70K | Buy |
+1,355
| New | +$68.5K | ﹤0.01% | 485 |
|
Other funds holding ABBV
VCM
VPM
Advisory Research's ABBV Position: Q1 2026 in Review
Advisory Research increased its AbbVie (ABBV) stake by 3.4% in Q1 2026, buying an estimated $528K and bringing the position to 73,072 shares worth $15.9M. The position accounts for 1.95% of the portfolio, ranked #19.
Advisory Research first reported a position in ABBV in Q1 2014 and has held it in 33 quarters since. The position peaked at $28.5M in Q1 2022. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Advisory Research held 73,072 shares of AbbVie worth $15.9M as of Q1 2026.
- Advisory Research bought 2,379 AbbVie shares in Q1 2026, an estimated $528K.
- AbbVie made up 1.95% of Advisory Research's portfolio in Q1 2026, its #19 holding.
- Advisory Research first reported a position in AbbVie in Q1 2014 and has held it in 33 quarters since.
- Advisory Research's AbbVie position peaked at $28.5M in Q1 2022.
- 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Advisory Research's 13F filing for Q1 2026, filed 14 May 2026.